These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 38570139)

  • 1. Effects of the induction of humoral and cellular immunity by third vaccination for SARS-CoV-2.
    Murayama G; Kusaoi M; Horiuchi Y; Tabe Y; Naito T; Ito S; Yamaji K; Tamura N
    J Infect Chemother; 2024 Oct; 30(10):1021-1027. PubMed ID: 38570139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
    Wagenhäuser I; Almanzar G; Förg FB; Stein A; Eiter I; Reusch J; Mees J; Herzog A; Vogel U; Frey A; Lâm TT; Schubert-Unkmeir A; Dölken L; Kurzai O; Frantz S; Gabel A; Petri N; Prelog M; Krone M
    Vaccine; 2024 Aug; 42(21):126132. PubMed ID: 39034219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.
    Liu WD; Lin MS; Sun HY; Shih MC; Chuang YC; Huang YS; Lin KY; Li GC; Wu PY; Chen LY; Liu WC; Su YC; He PC; Chen YT; Lin CY; Cheng YC; Yao Y; Yeh YC; Liu CC; Pan MY; Luo YZ; Chang HY; Wang JT; Sheng WH; Hsieh SM; Chang SY; Hung CC
    J Microbiol Immunol Infect; 2024 Aug; 57(4):554-563. PubMed ID: 38429206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-specific T helper cells and cytokine profiles predict intensity and longevity of cellular and humoral responses to SARS-CoV-2 booster vaccination.
    Page L; Dennehy K; Mueller K; Girl P; Loell E; Buijze H; Classen JM; Messmann H; Roemmele C; Hoffmann R; Wurster S; Fuchs A
    Front Immunol; 2024; 15():1423766. PubMed ID: 39267758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.
    Poh XY; Lee IR; Tan CW; Chavatte JM; Fong SW; Goh YS; Rouers A; Wong N; Torres-Ruesta A; Mah SYY; Yeoh AYY; Gandhi M; Rahman N; Chin YQ; Lim JJ; Yoong TJK; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim DRX; Chia W; Renia L; Ren EC; Lin RTP; Lye DC; Wang LF; Ng LFP; Young BE
    EBioMedicine; 2024 Sep; 107():105275. PubMed ID: 39137572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid immunity by two COVID-19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2.
    Almanzar G; Koosha K; Vogt T; Stein A; Ziegler L; Asam C; Weps M; Schwägerl V; Richter L; Hepp N; Fuchs A; Wagenhäuser I; Reusch J; Krone M; Geldmacher C; Protzer U; Steininger P; Überla K; Wagner R; Liese J; Prelog M
    J Med Virol; 2024 Jun; 96(6):e29739. PubMed ID: 38899449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.
    Zhang XS; Windau A; Meyers J; Yang X; Dong F
    Microbiol Spectr; 2024 Oct; 12(10):e0060524. PubMed ID: 39162540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
    Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
    J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
    Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
    Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
    Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
    J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
    Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
    EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
    Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
    Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
    Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
    Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
    Ying B; Liang C-Y; Desai P; Scheaffer SM; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    J Virol; 2024 Sep; 98(9):e0057424. PubMed ID: 39194250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
    Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C
    EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel.
    Romero-Ibarguengoitia ME; Rivera-Salinas D; Hernández-Ruíz YG; Armendariz-Vázquez AG; González-Cantú A; Barco-Flores IA; González-Facio R; Montelongo-Cruz LP; Del Rio-Parra GF; Garza-Herrera MR; Leal-Meléndez JA; Sanz-Sánchez MÁ
    PLoS One; 2022; 17(3):e0263942. PubMed ID: 35235587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers.
    Suwarti S; Lazarus G; Zanjabila S; Sinto R; Fransiska F; Deborah T; Oktavia D; Junaidah J; Santayana S; Surendra H; Yuliana J; Pardosi H; Nuraeni N; Soebianto S; Susilowati ND; Subekti D; Pradipta A; Baird JK; Tan LV; Dunachie S; Shankar AH; Nelwan EJ; Hamers RL;
    BMC Infect Dis; 2024 Aug; 24(1):768. PubMed ID: 39090537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.